MSKCC in the News: October 8 – October 19

Posted on October 22, 2012 by Donna

Curbing Overpriced Treatments for Cancer Care. Dr. Peter Bach from the department of Epidemiology-Biostatistics is mentioned in this article from The Fiscal Times.
Memorial Sloan-Kettering Dx Molecular Pathology Lab Developing Cancer Panels on Illumina. Drs. Cyrus Hedvat, Michael Berger, and Ross Levine are mentioned.
A letter in The New York Times entitled “In Cancer Care, Cost Matters” written by Peter B. Bach, Leonard B. Saltz, and Robert E. Wittes, doctors from MSKCC discuss their reason to not support an expensive new cancer drug.

MSKCC in the News: September 20 – October 5

Posted on October 10, 2012 by Donna

Congratulations to the following Sloan-Kettering Institute researchers. They are the recipients of the 2012 NIH Director’s New Innovator Award Program: Ping Chi, M.D., Ph.D., An integrative approach to target lineage-specific oncogenic transcription factor; Daniel A. Heller, Ph.D.,Transient Metabolite Detection for Single-Cell Metabolomics and Diagnostics; and Alexandrosc Pertsinidis, Ph.D., Understanding Gene Transcription from First-Principles: A single-molecule study. View all recipients.
Investigators at MSKCC, Weill Cornell Medical College, Johns Hopkins University, and The Rockefeller University have found that the nonsteroidal anti-inflammatory drug oxyphenbutazone (OPB) is an effective antimycobacterial agent that displays potent activity against nonreplicating as well as replicating populations of the bacterium.
Sloan-Kettering & Hunter College to Build High-Tech NYC Cancer Center.
The National Cancer Institute awarded the Small Business Innovation Research grant to RXi for a project with Dr. David Cobrinik and others at Memorial Sloan-Kettering Cancer Center.

Posted on September 17, 2012 by Mark

Last week Mayor Bloomberg, MSKCC, CUNY and Hunter College announced plans to build two new science and medical facilities on the Upper East Side.
The New York Times reported that veterinarians from the Animal Medical Center began meeting with their counterparts at MSKCC to set up trials of a noninvasive device for removing tumors of the urinary tract with electrical impulses.
Acupuncture for the treatment of chronic pain is better than placebo acupuncture (sham acupuncture) or no acupuncture at all, researchers from MSKCC wrote in the JAMA journal Archives of Internal Medicine.
In a recent study published in the New England Journal of Medicine, MSKCC’s Howard I. Scher and colleagues found that men with metastatic castration-resistant prostate cancer after chemotherapy have improved survival and secondary end points after treatment with enzalutamide vs. placebo.